Aveo Pharma's Tivozanib Trips on Overall Survival Data

In its second quarterly earnings report for 2012, Aveo Pharmaceuticals Inc., of Cambridge, Mass., said the FDA is concerned about overall survival trends in its ongoing TIVO-1 trial of tivozanib compared to sorafenib (Nexavar, Onyx Pharmaceuticals Inc.) in 517 patients with advanced renal cell carcinoma.